𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Current status of molecular targeted therapy for hematologic malignancies: introduction

✍ Scribed by Ueda, Takanori

Book ID
121549077
Publisher
Springer
Year
2013
Tongue
English
Weight
106 KB
Volume
19
Category
Article
ISSN
1341-9625

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Mammalian target of rapamycin inhibition
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies
✍ Amit Panwalkar; Srdan Verstovsek; Francis J. Giles πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 588 KB

## Abstract The mammalian target of rapamycin (mTOR) is a downstream effector of the phosphatidylinositol 3‐kinase (PI3K)/Akt (protein kinase B) signaling pathway, which mediates cell survival and proliferation. mTOR regulates essential signal‐transduction pathways, is involved in the coupling of g

Mammalian target of rapamycin inhibition
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies
✍ Corey Cutler; Joseph H. Antin πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 32 KB

P anwalkar and colleagues present a very complete overview on the evolving role of mammalian target of rapamycin (mTOR) inhibitors in the treatment of both hematologic and nonhematologic malignancies. We wish to clarify selected statements made by the authors. We would like to point out that all mT